ICI Conference 2025

We are still finalizing the program, but we are truly honored to already share that the following speakers have confirmed their participation:
 
Alexander Kros is professor of supramolecular chemistry at the Faculty of Science of the University Leiden. He is interested to obtain curiosity-driven and fundamental molecular-level insight into transport phenomena related to drug delivery. One of the long-standing grand challenges in the nanomedicine field is the delivery problem, which can be better understood and potentially solved when (in vivo) transport phenomena are understood at the molecular level.
 
Carl Figdor is professor in Experimental Immunology (in particular, Tumor Immunology) and head of the Tumor Immunology Department at the Radboud University Medical Center in Nijmegen. Until 2010 he was the scientific director of the NCMLS (now RIMLS). His research interests include immunology and cell biology, with a specific focus on the molecular mechanisms controlling antigen presenting cells, in particular dendritic cells. Major current projects include investigation of the role of lectin-like receptors in antigen uptake and the role of the cytoskeleton in dendritic cell adhesion and migration. The use of high resolution single cell imaging tools to achieve greater insights into the topography of cell surface receptors and the advancement of translational medicine through the treatment of cancer patients using antigen loaded dentritic cell vaccines are among his current fascinations as an immunologist. Furthermore, Carl Figdor is CSO and co-founder of Simmunext Biotherapeutics, a company that uses its proprietary polymer-based nanotechnology platform to mimic natural immune cell function.

Li Tang is associate professor at the Laboratory of biomaterials for immunoengineering at the École Polytechnique Fédérale de Lausanne, Switzerland. His fields of expertise are immunoengineering, immune metabolism, mechano-immunology, biomaterials and cancer immunotherapy. Our immune system is continuously defending us against a wide range of diseases through complex interactions with invaders and diseased cells. These interactions are profoundly multi-dimensional, involving intricate biological, chemical, and physical exchanges. With this in mind, the team at Tang’s Laboratory is developing innovative strategies to engineer these multi-dimensional immunity-disease interactions — an emerging field known as ‘immunoengineering’ — aiming to create safe and effective therapies against cancer.

Mirjam Heemskerk is professor of Cancer Immunotherapy and head of the Laboratory for Experimental Hematology at the Leiden University Medical Center. She leads a translational research group focused on developing novel cellular immunotherapies for patients with cancer. In 2013, partly under her leadership, the first phase I/II TCR gene therapy study for hematological malignancies after allogeneic stem cell transplantation was started (EudraCT number 2010-024625-20). Two new phase I/II TCR studies are currently being set up within the Hematology department, one for patients with acute myeloid leukemia (NPM1-TCR), the other for patients with multiple myeloma (BOB1-TCR).

Did you sign up, but are unfortunately unable to attend? To make your spot available for someone else, and to prevent cost and/or food waste, please inform us by email (ICI@lumc.nl) before November 5th, 2025.